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Abstract
Background Colorectal cancer remains a common cause of cancer death in the UK, with surgery being the mainstay of 
treatment. An objective measurement of the suitability of each patient for surgery, and their risk–benefit calculation, would 
be of great utility. We postulate that sarcopenia (low muscle mass) could fulfil this role as a prognostic indicator. The aim 
of this study was to determine the relationship between sarcopenia and long-term outcomes in patients undergoing elective 
bowel resection for colorectal cancer.
Methods One hundred and sixty-three consecutive patients who had elective curative colorectal resection for cancer were 
eligible for inclusion in the study. Psoas muscle mass was assessed on preoperative computed tomography scan at the level 
of the L3 vertebra and standardised for patient height (total psoas index, TPI). Sarcopenia (low muscle mass) was defined 
as < 524 mm2/m2 in males and 385 mm2/m2 in females. In addition to clinical–pathological parameters, postoperative com-
plications were recorded and patients were followed up for mortality for 1 year after surgery.
Results Sarcopenia was present in 19.6% of the study participants and was significantly related to body mass index 
(p = 0.007), 30-day mortality (p = 0.042) and 1-year mortality (p = 0.046). In univariate analysis, American Society of 
Anesthesiologists grade (p = 0.016), tumour stage (p = 0.018) and sarcopenia (p = 0.043) were found to be significant inde-
pendent predictors of 1-year mortality.
Conclusions This study has found sarcopenia to be prevalent in patients with colorectal cancer having elective surgery. 
Independent of age, sarcopenia was associated with poorer 30-day mortality and survival at 1 year. Measurement of mus-
cle mass preoperatively could be used to stratify a patient’s risk, allowing targeted strategies such as prehabilitation, to be 
implemented to modify sarcopenia and improve long-term outcomes for patients.
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Introduction
Colorectal cancer is the fourth most common cancer in the 
UK, with over 41,000 new diagnoses in 2014 [1]. With 
incidence increasing with age, and the ageing population 
expanding, there is a clinical need for new prognostic knowl-
edge-aided decision making to improve long-term outcomes 
[2, 3]. One potential prognostic marker is sarcopenia. Sarco-
penia was defined in 2010 as ‘a syndrome characterised by 
progressive and generalised loss of skeletal muscle mass and 
strength’ (the European Working Group on Sarcopenia in 
Older People (EWGSOP) [4]. There are various techniques 
available to measure sarcopenia, varying from simple to 
complex, but computed tomography (CT) measurement of 
the psoas muscle, with established cutoffs defining sarcope-
nia, is a widely accepted technique [4].
There have been numerous studies that have assessed the 
relationship between sarcopenia and surgical outcomes in 
patients having various intra-abdominal operations, includ-
ing radical cystectomy, liver transplantation and emergency 
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general surgery, with their findings pointing towards an asso-
ciation between sarcopenia and mortality [5–8].
Studies specifically analysing the influence of sarcope-
nia on postoperative elective colorectal cancer patients have 
found that the presence of sarcopenia results in an increased 
risk of postoperative complications, increased length of hos-
pital stay and increased cost of care [9–15]. A study pub-
lished in 2019 showed that sarcopenia is highly predictive 
of serious postoperative complications in colorectal cancer 
patients [15]. In contrast, there are only a few studies focus-
ing on the relationship between sarcopenia and long-term 
mortality [16–19]. Although all suggested a negative influ-
ence of sarcopenia on 1-year survival, drawing conclusions 
is difficult due to the different patient populations studied 
and varying methodologies.
The primary aim of this study was to determine the 
relationship between preoperative sarcopenia and mortal-
ity at 1 year in patients who had elective colorectal cancer 
resection.
Materials and methods
Data sources and study population
The study was registered with the NHS Greater Glasgow 
and Clyde Clinical Effectiveness Department (August 2016). 
Analysis was undertaken of data extracted from the prospec-
tive enhanced recovery after surgery (ERAS) database at 
the Royal Alexandra Hospital, Paisley, for the period Janu-
ary 2015–December 2016. This database has been set up 
as a part of the National Enhanced Recovery Colorectal 
Initiative (NERCI) supported by the Whole System Patient 
Flow Improvement Programme as part of the Scottish 
Government’s Health Performance and Delivery Directo-
rate. Briefly, data from all elective colorectal surgery (both 
benign and malignant pathology) are submitted from each 
surgical unit in Scotland every month with regular feedback 
after central analysis of the data.
Inclusion criteria extended to any patient who had elec-
tive colorectal resection with curative intent, where pathol-
ogy had confirmed colonic or rectal adenocarcinoma. Stage 
4 patients with resectable liver and lung metastases, as 
adjudged by the relevant clinical specialists, were included. 
Patients were excluded if: they had received neo-adjuvant 
therapy; had surgery to treat any condition other than colo-
rectal cancer; had widespread unresectable metastatic dis-
ease; had surgery as an emergency; if no preoperative CT 
scan was available; or if their most recent CT scan was per-
formed more than 4 months before surgery.
Demographic, anthropometric and clinical data including 
height, weight, body mass index (BMI) [weight (kg)/height 
(m)2], American Society of Anesthesiologists (ASA) score, 
operative procedure, American Joint Committee on Cancer 
(AJCC) TNM stage [20], length of hospital stay (days), post-
operative complications and grade [21] and re-admission 
to the hospital within 30 days were analysed. In addition, 
patients’ electronic records were followed up for mortality 
for 1 year after the date of surgery.
Sarcopenia measurement: CT scan analysis
To measure sarcopenia in each patient, the total cross-sec-
tional area of the psoas muscles (total psoas area, TPA) was 
measured using a manual technique at the level of the L3 
vertebra on preoperative CT (median interval between CT 
scan and surgery was 38 days, range 2–119 days) [22]. To 
ensure standardisation, the exact level of measurement was 
defined as the CT slice in which both L3 transverse pro-
cesses were maximally in view. Area was measured using a 
free-hand drawing technique on Picture Archiving and Com-
munication System (PACS) software (Fig. 1). The outline of 
each individual psoas muscle was traced, the area of each 
calculated, and summated to provide the TPA  (mm2). The 
TPA was then standardised for patient height using the for-
mula: TPA  (mm2)/height  (m2). This provided the total psoas 
index (TPI) for each patient.
For the purposes of this study, the threshold values used 
for the diagnosis of sarcopenia are the same as those used by 
Prado et al. in their widely cited 2008 paper [23]: 524 mm2/
m2 for males and 385 mm2/m2 for females. All individuals 
with a TPI below this threshold for their gender were classi-
fied as sarcopenic. For the purposes of this study, sarcopenia 
is defined as an absolute variable; patients were either sar-
copenic or non-sarcopenic.
To ensure reliability of our technique, 20 scans were ran-
domly selected and measured for  TPI  by blindly trained 
investigators to allow calculation of inter- and intra-class 
correlation coefficients (ICCC). The ICCC values for inter- 
and intra-class reliability were 0.94 and 0.99, respectively 
(values close to 1 indicate excellent agreement).
Statistical analysis
Relevant variables were transcribed to SPSS version 21 
[24] to enable statistical analysis. Descriptive statistics were 
used to characterise the patient population, with continu-
ous variables summarised by median and interquartile range 
and categorical variables presented in tabulated form with 
percentages. Continuous variables were tested using non-
parametric methods.
To determine the primary outcome of the influence of 
sarcopenia on survival at 1 year, survival analysis using 
log-rank testing was performed. Further exploration of vari-
ables influencing mortality was performed using univariate 
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analysis and a Cox proportional hazards model. The level of 
significance was set at 5%.
Results
Patient demographics, physiological 
and pathological characteristics
Over the study period, 331 patients had elective colorectal 
surgery, with 163 (49.2%) eligible for inclusion in the study 
(Fig. 2). The median age of the cohort was 70 years (IQR 
61–75) and 99 (60.7%) were male. The majority of surgery 
was for patients with rectal cancer who had an ASA of 2 
and 112 (68.7%) were overweight or obese. One hundred 
and forty-nine (91.4%) had a pathological R0 resection with 
only 8.6% of patients having a major complication leading 
to a median length of the hospital stay of 8 days (IQR 6–12) 
[Table 1]. Eleven patients had stage 4 tumours, however, 
these patients had lung/liver metastases that were considered 
resectable and so they were operated on with curative intent.
Sarcopenia
Overall, 32 (19.6%) patients having elective colorectal can-
cer surgery were sarcopenic: 18/99 males (18.2%) (Fig. 3) 
and 14/64 females (21.9%) (Figs. 3, 4). The characteristics of 
the sarcopenic and non-sarcopenic groups are compared in 
Table 2. Significant differences were noted between the two 
groups in the categories: BMI (p = 0.007), 30-day mortality 
(p = 0.042) and 1-year mortality (p = 0.046). Here, the sar-
copenic patients were more likely to be classified as under-
weight and have increased postoperative mortality at 30 days 
and 1 year [Fig. 5].   
Survival at 1 year
For the whole patient cohort, univariate analysis found sar-
copenia (p = 0.043), tumour stage (p = 0.018), ASA grade 
(p = 0.016) and major complications (p = 0.021) to be sig-
nificantly associated with survival at 1 year. Multivariable 
analysis revealed that only ASA grade and tumour stage 
were significantly independent predictors of mortality at 
1 year (p = 0.042 and p = 0.007, respectively) (Table 3).
Discussion
This study demonstrated that sarcopenia is prevalent, 
occurring in nearly one-fifth of the patients having elective 
colorectal cancer surgery. In addition to confirming that 
sarcopenia places patients at greater risk of postoperative 
complications, this work has found sarcopenia also nega-
tively influences survival at 1 year after curative surgery.
These results have strengths over the previous publica-
tions looking at 1 year survival. It is prospective and con-
tains both colon and rectal cancer patient populations, not 
just rectal [18]. In addition, two of the previous studies 
assessed sarcopenia in Asian populations, and members of 
these populations have accepted differences in lifestyle and 
Fig. 1  CT image at the level of the L3 vertebra, demonstrating the method of outlining the left (green) and right (red) psoas muscle and measur-
ing their respective areas
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body habitus when compared to the western population [18, 
19]. For example, in the paper by Choi et al., mean age of 
the patients was 61.3 years and mean BMI was 23.8 kg/m2. 
These figures are both significantly lower than in the cohort 
of patients included in this study. Overall, our findings are 
more applicable to the western colorectal cancer patients, 
Patients on ERAS database 
2015/16 
n = 331
Patients with colorectal 
cancer 
n = 219
Patients who underwent 
primary bowel resection
n = 172
Patients included in final 
analysis
n = 163
Exclusions n = 112
• 48 diverticular disease
• 21 Crohn’s disease
• 13 ulcerative colitis
• 11 polyp cancers
• 3 volvulus
• 16 other
Exclusions n = 47
• 31 reversal of ileostomy
• 10 creation of a 
defunctioning colostomy
• 4 revisions of stoma
• 2 conversions of 
anastomoses 
Hartmann
Exclusions n = 9
• 5 no CT scan for 
assessment
• 4 duplicate patients
Fig. 2  Patient flowchart for the study and reasons for exclusion of 
individuals. ERAS enhanced recovery after surgery
Table 1  Baseline demographics, clinical, and pathological character-
istics of the patients underdoing elective surgery for colorectal cancer
Characteristic n (%)
Sex
 Male 99 (60.7)
 Female 64 (39.3)
Median age, years (IQR)
70 (61–75)
Age category, years
 < 65 57 (35)
 65–74 59 (36.2)
 ≥ 75 47 (28.8)
BMI category kg/m2
 Underweight 4 (2.5)
 Normal 47 (28.8)
 Overweight 67 (41.1)
 Obese 45 (27.6)
ASA grade
 1 4 (2.5)
 2 101 (62)
 3 56 (34.4)
 4 2 (1.2)
TNM stage
 0 8 (4.9)
 1 34 (20.9)
 2 57 (35)
 3 53 (32.5)
 4 11 (6.7)
Site of cancer
 Colon 72 (44.2)
 Rectum 91 (55.8)
Procedure
 Right hemicolectomy 52 (31.9)
 Left hemicolectomy or sigmoid colectomy 15 (9.2)
 Total or sub-total colectomy 6 (3.7)
 Anterior resection 65 (39.9)
 APER 25 (15.3)
Resection margin
 R0 149 (91.4)
 R1 14 (8.6)
In-hospital complication
 Yes 91 (55.8)
 No 72 (44.2)
Major in-hospital complication*
 Yes 14 (8.6)
 No 149 (91.4)
Median length of stay (IQR), days
8 (6–12)
Re-admitted within 30 days
 Yes 21 (12.9)
 No 142 (87.1)
Sarcopenic
 Yes 32 (19.6)
 No 131 (80.4)
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adding to the evolving evidence that sarcopenia is a negative 
prognostic factor for patients having elective gastrointestinal 
Table 1  (continued)
*Complications classified as 3 or greater on the Clavien–Dindo scale
ASA American Society of Anesthesiologists, AJCCTNM American 
Joint Committee on Cancer TNM stage, BMI body mass index
Fig. 3  Scatterplot showing the 
spread of TPI values for male 
patients and the threshold for 
sarcopenia
Fig. 4  Scatterplot showing the 
spread of TPI values for female 
patients and the threshold for 
sarcopenia
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oncological surgery, and more specifically, colorectal 
resection.
The mechanism underlying the significant relationship 
between sarcopenia and 1-year mortality requires discussion. 
It may be indicative of the presence of sub-clinical synchro-
nous metastasis, which is subsequently picked up during fol-
low-up after surgery. If this is the case, then sarcopenia may 
highlight patients who would benefit from more extensive 
staging investigations, such as positron emission tomogra-
phy (PET) scanning. This may lead to the consideration of 
preoperative chemotherapy and/or more frequent clinical and 
radiological follow-up with the aim of improving outcomes. 
An alternative explanation is that sarcopenia indicates that 
patients have poorer physical capacity, making them less 
resilient to the physiological stresses of surgery and more at 
risk of complication [15]. Indeed, the relationship between 
sarcopenia and frailty is well documented [25]. This raises 
the possibility that, unlike other preoperative prognostic 
markers (e.g. TNM staging), sarcopenia could be modified 
via prehabilitation. This individualised physical activity-cen-
tred intervention is delivered in the period between diagno-
sis and the commencement of treatment for cancer and has 
been shown to be feasible, safe and reduce postoperative 
complications in patients treated for colorectal cancer [26, 
27], although may not always produce improvements in fit-
ness. Furthermore, a recent systematic review has demon-
strated that the positive effects of prehabilitation can be seen 
after as little as 2 weeks [28]. Therefore, the pretreatment 
measurement of sarcopenia could offer an effective way of 
selecting patients who would benefit the most from such 
targeted, individualised prehabilitation [29]. Individualised 
prehabilitation programmes will require adequate funding 
to introduce; however, we do not expect interventions to be 
particularly costly, and would hope that the institution of 
prehabilitation would lead to savings in resources due to 
reduced morbidity and shortened stays in hospital.
The strengths of our study were that the data were col-
lected prospectively and are reviewed centrally on a monthly 
basis, minimising the likelihood of any inaccuracy in the 
measurement or recording of variables. The method used 
to measure sarcopenia is simple and easy to learn, low cost, 
valid, and requires no investment from healthcare provid-
ers, meaning it could be seamlessly integrated into the care 
pathway for colorectal cancer patients. This is in contrast 
to other methods of skeletal muscle measurement that use 
costly specialist software packages that require additional 
training.
It is important to acknowledge several limitations of this 
work. First, this is a single-centre study and future work 
should be multi-centred to allow greater number of patients 
with colorectal cancer to be included. A multi-centre study 
would also allow the inclusion of a more ethnically diverse 
population and subsequent subgroup analysis. Second, 
Table 2  Demographics, clinical, and pathological characteristics of 
patients with sarcopenia compared to patients without sarcopenia
Complications classified as 3 or greater on the Clavien–Dindo scale
ASA American Society of Anesthesiologists, AJCCTNM American 
Joint Committee on Cancer TNM stage, BMI body mass index
*P < 0.05: level of significance
Sarcopenic (n = 32) Non-sarcopenic 
(n = 131)
p value
Sex
 Male 18 (56.3) 81 (61.8) 0.350
 Female 14 (43.8) 50 (38.2)
Age category, years
 < 65 8 (25.0) 49 (37.4) 0.412
 65–74 13 (40.6) 46 (35.1)
 ≥ 75 11 (34.4) 36 (27.5)
BMI category kg/m2
 Underweight 3 (9.4) 1 (0.8) 0.007*
 Normal 13 (40.6) 34 (26.0)
 Overweight 11 (34.4) 56 (42.7)
 Obese 5 (15.6) 40 (30.5)
Median ASA (SD)
2 (0.56) 2 (0.55) 0.542
TNM stage
 0 3 (9.4) 5 (3.8) 0.194
 1 3 (9.4) 31 (23.7)
 2 12 (37.5) 45 (34.4)
 3 12 (37.5) 41 (31.3)
 4 2 (6.3) 9 (6.9)
Site of cancer
 Colon 17 (53.1) 55 (42.0) 0.174
 Rectum 15 (46.9) 76 (58.0)
Resection margin
 R0 30 (93.8) 119 (90.8) 0.598
 R1 2 (6.3) 12 (9.2)
In-hospital complication
 Yes 14 (43.8) 73 (55.7) 0.957
 No 18 (56.3) 60 (44.3)
Major in-hospital complication
 Yes 2 (6.3) 12 (9.2) 0.598
 No 30 (93.8) 119 (90.8)
Median length of stay (IQR), days
8 (6–12) 8 (6–12) 0.567
Re-admitted within 30 days
 Yes 3 (9.4) 18 (13.7) 0.509
 No 28 (90.6) 113 (86.3)
Alive at 30 days
 Yes 31 (96.9) 131 (100) 0.042*
 No 1 (3.1) 0 (0)
Alive at 90 days
 Yes 31 (96.9) 130 (0.8) 0.277
 No 1 (3.1) 1 (99.2)
Alive at 1 year
 Yes 27 (84.4) 124 (94.7) 0.046*
 No 5 (15.6) 7 (5.3)
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although all scans were performed within 4 months of sur-
gery, it is possible that the skeletal muscle mass could have 
changed before surgery. Furthermore, the use of predefined 
cutoffs for sarcopenia has been defined in populations, which 
are not necessarily homogenous to the population included 
in this study. For example, the Prado sarcopenia cutoffs used 
in this study were defined in an obese population in Canada, 
with tumours of the respiratory and gastrointestinal tracts. 
However, using predefined cutoffs is preferable to arbitrar-
ily concluding that patients in the lowest quartile for muscle 
mass are sarcopenic. Lastly, 30-day mortality was related to 
sarcopenia in this study. However, this finding was driven 
by a single death in the cohort and should be interpreted 
with caution.
Conclusions
This study has found sarcopenia to be prevalent in colo-
rectal cancer patients having elective surgery, resulting 
in poorer long-term survival. CT measurement of total 
psoas mass is a valid and simple technique for diagnosing 
sarcopenia that could be used to augment existing methods 
of patient-risk stratification prior to surgery. Such sarco-
penic patients could then undergo targeted strategies such 
Fig. 5  Comparison of 1-year 
mortality between colorectal 
cancer patients with sarcopenia 
and those without sarcopenia
Table 3  Univariate and 
multivariable analyses of factors 
influencing survival at 1 year 
in patients who have undergone 
elective surgery for colorectal 
cancer
ASA American Society of Anesthesiologists, BMI body mass index
a Included preoperative variables that had been identified as significant in univariate analysis
Univariate analysis Multivariable  analysisa
Variable Log-rank p value Hazard ratio 95% CI p value
Sarcopenia 0.043 2.233 0.665–7.504 0.194
TNM stage 0.018 2.609 1.307–5.208 0.007
ASA 0.016 2.861 1.037–7.892 0.042
Major complication 0.021 – – –
BMI category 0.225 – – –
Age group 0.546 – – –
Gender 0.418 – – –
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as prehabilitation, to improve both their short- and long-
term outcomes.
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